Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 10/20 | 0.39 |
| ▸ | CNR1 | P21554 | 5/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.39 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.39 |
| ▸ | CD38 | P28907 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.37 |
| ▸ | BAD | Q92934 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6894406 | 0.90 | MAPK8 (0.42) | CNR2CNR1SLC6A3GUCY1A1GUCY1B1 | |
| SCHEMBL6776083 | 0.90 | PLA2G1B (0.42) | CNR2PLA2G1BPLA2G2ACD38F10 | |
| SCHEMBL6778663 | 0.89 | CNR2 (0.42) | PPARGCNR2CNR1PLA2G2ACD38 | |
| SCHEMBL6782670 | 0.88 | ALDH1A1 (0.39) | PPARGCNR2CNR1 | |
| SCHEMBL6771775 | 0.88 | PPARG (0.39) | PPARGCNR2CNR1CD38 | |
| SCHEMBL6775148 | 0.88 | CNR1 (0.42) | PPARGCNR2CNR1PLA2G2A | |
| SCHEMBL6778298 | 0.87 | CNR1 (0.43) | PPARGCNR2CNR1PLA2G1BPLA2G2A | |
| SCHEMBL5212214 | 0.87 | PPARG (0.46) | PPARGPLA2G2A | |
| SCHEMBL6776818 | 0.86 | PPARG (0.45) | PPARGPLA2G1BPLA2G2A | |
| SCHEMBL6776370 | 0.86 | PPARG (0.44) | PPARGCNR2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |